Abstract: Crude soybean oil (CSO) is used to increase metabolizable energy (ME) content in diets for laying hens. Also used in human food, its price is consequently high. Oil soapstocks are byproducts of the oil extraction process and therefore cost less. An evaluation was done of the effect of two soybean soapstocks (SS) on egg production, quality and lipid composition, and the cost of 1 kilogram of eggs. Soapstock ME and lipid composition were quantified. An experiment was done using 240 hens in six treatments, with five replicates and eight hens per replicate. Diets were formulated using CSO, or one of the soapstocks, at 2 or 4% concentrations. The evaluated productive variables were feed intake, feed conversion, egg weight, egg mass, laying percentage and egg quality parameters. Egg lipid composition was described and the cost per one kilogram calculated. Replacement of CSO with the soapstocks did not affect poultry production variables (P>0.05), but did improve Haugh unit values (P<0.05). Egg fatty acids composition changed in response to oil composition (P<0.05), and inclusion concentration affected the levels of specific fatty acids. Use of the soapstocks resulted in a lower cost per kilogram of eggs than with CSO (P<0.05). Substitution of crude soy oil with the evaluated soapstocks had no effect on productive variables, improved egg quality and lowered overall feed costs.

Resumen: En la alimentación de gallinas en postura se utiliza el aceite crudo de soya (ACS), pero debido a que éste compite con la alimentación humana su precio es alto, por lo cual se evaluaron dos aceites acidulados de soya (AAS), los cuales son más económicos. El objetivo del estudio fue evaluar el efecto de los AAS en la producción de gallinas Bovans, calidad de huevo, composición lipídica y costo de un kilo de huevo. Se determinó la energía metabolizable (EM) y composición de lípidos de los acidulados. Se utilizaron 240 gallinas en seis tratamientos, con cinco repeticiones, con ocho gallinas cada una. En las dietas se incluyeron ACS y dos acidulados (AAST y AASY), a dos niveles (2% y 4%). Las variables productivas fueron alimento consumido, porcentaje de postura, peso del huevo, masa del huevo, conversión alimenticia; en calidad de huevo se midió altura de albumina, unidades Haugh (UH), color de yema y grosor de cascarón. Se determinó la composición lipídica del huevo y su costo. Al sustituir el ACS por los AAS no se afectó la producción de las aves (P>0.05). En calidad de huevo, los AAS mejoraron las UH (P<0.05); la concentración de ácidos grasos del huevo se modificó según la composición del aceite en la dieta de las gallinas (P<0.05), mientras que el nivel de aceite influyó en el contenido de algunos ácidos grasos. Finalmente los AAS disminuyeron el costo de un kilo de huevo (P<0.05) en comparación del ACS.

Objective. To estimate direct medical costs (DMC) associated with treatment of Respiratory Distress Syndrome (RDS) in newborns (NB) in two specialized public hospitals in Mexico. Materials and methods. The perspective used was health care payer. We estimated DMC associated with RDS management. The pattern of resource use was established by reviewing clinical records. Microcosting and bootstrap techniques were used to obtain the DMC. Estimated costs were reported in 2011 US dollars. Results. Average DMC per RDS event was 14 226 USD. The most significant items that account for this cost were hospitalization (38%), laboratory and diagnostic exams (18%), incubator time (10%), surfactant therapy (7%), and mechanical ventilation (7%). Conclusion. Average DMC in NB with RDS fluctuated in relation to gestational age weight at birth and clinical complications presented by patients during their hospitalization.

Objetivo. Determinar los costos médicos directos (CMD) asociados con el tratamiento del síndrome de dificultad respiratoria (SDR) en recién nacidos pretérmino en dos hospitales públicos de alta especialidad de México. Material y métodos. Se utilizó la perspectiva del pagador de servicios de salud. El uso de recursos se estimó mediante la revisión de expedientes clínicos. Se empleó la técnica de microcosteo y de bootstrap para la obtención de los CMD. Los costos fueron reportados en dólares estadounidenses de 2011. Resultados. El CMD por evento de SDR promedio fue de 14 226 dólares distribuidos entre los costos de hospitalización (38%), laboratorio y exámenes de diagnóstico (18%), tiempo en incubación (10%), terapia con surfactantes (7%) y ventilación mecánica (7%). Conclusión. Los CMD promedio en recién nacidos pretérmino con SDR están relacionados con la edad gestacional, el peso al nacer y las complicaciones clínicas que presentan los pacientes durante su hospitalización.

Objective. To estimate direct medical costs (DMC) associated with treatment of Respiratory Distress Syndrome (RDS) in newborns (NB) in two specialized public hospitals in Mexico. Materials and methods. The perspective used was health care payer. We estimated DMC associated with RDS management. The pattern of resource use was established by reviewing clinical records. Microcosting and bootstrap techniques were used to obtain the DMC. Estimated costs were reported in 2011 US dollars. Results. Average DMC per RDS event was 14 226 USD. The most significant items that account for this cost were hospitalization (38%), laboratory and diagnostic exams (18%), incubator time (10%), surfactant therapy (7%), and mechanical ventilation (7%). Conclusion. Average DMC in NB with RDS fluctuated in relation to gestational age weight at birth and clinical complications presented by patients during their hospitalization.

Objetivo. Determinar los costos médicos directos (CMD) asociados con el tratamiento del síndrome de dificultad respiratoria (SDR) en recién nacidos pretérmino en dos hospitales públicos de alta especialidad de México. Material y métodos. Se utilizó la perspectiva del pagador de servicios de salud. El uso de recursos se estimó mediante la revisión de expedientes clínicos. Se empleó la técnica de microcosteo y de bootstrap para la obtención de los CMD. Los costos fueron reportados en dólares estadounidenses de 2011. Resultados. El CMD por evento de SDR promedio fue de 14 226 dólares distribuidos entre los costos de hospitalización (38%), laboratorio y exámenes de diagnóstico (18%), tiempo en incubación (10%), terapia con surfactantes (7%) y ventilación mecánica (7%). Conclusión. Los CMD promedio en recién nacidos pretérmino con SDR están relacionados con la edad gestacional, el peso al nacer y las complicaciones clínicas que presentan los pacientes durante su hospitalización.

Background: Medical Insurance Siglo XXI (MISXXI) in Mexico provides funds for the medical and preventive care of children from households lacking any health insurance, thus seeking to reduce impoverishing due to health problems. This paper analyzes mortality of children <2 years of age affiliated with this program and out-of-pocket expenses attributable to this event. Methods: An in-home survey addressed to determine the health conditions of children affiliated with MISXXI was carried out in all Mexican states. If the infant had died, information was collected with emphasis on diagnosis (death certificate), medical attention and out-of-pocket expenses. Diagnoses were classified in agreement with ICD-10. Results: Of 9181 children, 74 died by the time during which the survey was gathered; 51% of children died before 28 days. Deaths were attributable to short gestation, low birth weight, asphyxia, or sepsis. In newborns who died before 7 days of age, 95.7% received medical care; however, among those who died between 7 and 28 days, only 58% received medical care. During the neonatal period, medical care was predominantly given in the Ministry of Health facilities. During the post-neonatal period, almost all children received medical care, predominantly in private facilities, a reason for households incurring in out-of-pocket expenditures. Conclusions: Mortality of infants who are beneficiaries of MISXXI mainly occurs during the neonatal period; however, households incurred in out-of-pocket expenditures, especially in the post-neonatal period. It seems convenient to boost the access of users to benefits provided by this medical insurance.

Demência e transtorno cognitivo leve (CCL) é uma entidade clínica cada vez mais prevalente, mostrando uma incidência crescente com a idade. OBJETIVO: O objetivo deste estudo foi o de identificar os principais tipos de demência e CCL tratados em uma unidade de transtornos da memória de Costa Rica. MÉTODOS: Um registo consecutivo e padronizado de pacientes com diagnóstico de demência e CCL na unidade de transtorno de memória do Hospital Geral de Geriatria e Gerontologia. RESULTADOS: Demência foi diagnosticada em 63,5% dos 3.572 casos, enquanto 10,6% tiveram diagnóstico de CCL. O tipo mais frequente de demência foi a doença de Alzheimer (47,1%), seguido de doença vascular (28,9%), formas mistas (17,2%) e outros tipos (6,8%). No CCL, 69,5% eram de tipo amnéstico de múltiplos domínios e 14,3% eram não-amnéstcios de múltiplos domínios, enquanto 41,3% eram de etiologia vascular e 35,8% de etiologia neurodegenerativa. A média de idade foi de 79,6±6,7 anos e 64,7% eram mulheres em casos de demência ao passo que a média de idade foi de 76,4±6,9 anos e 62,1% eram mulheres nos casos de CCL. A média de anos de estudo foi de 4,95±4,09 anos e 6,87±4,71, o tempo entre o início dos sintomas eo diagnóstico clínico médio foi de 3,2±2,6 anos e 2,67±2,69 anos em demência e CCL, respectivamente. CONCLUSÃO: A determinação dos principais tipos de demência e CCL na Costa Rica e as suas principais características permitiu o registro de informação abundante que era desconhecida e que será útil para a gestão e planejamento estratégico da saúde pública.

Dementia and mild cognitive impairment (MCI) are an increasingly prevalent clinical entity in our field, showing an increasing incidence with age. OBJECTIVE: The purpose of this study was to identify the main types of dementia and MCI treated in a memory disorders unit in Costa Rica. METHODS: A consecutive and standardized register of patients diagnosed with dementia and MCI at the memory disorders unit of the National Geriatrics and Gerontology Hospital (NGGH) was analyzed. RESULTS: Dementia was diagnosed in 63.5% of the 3572 cases, whereas 10.6% met criteria for MCI. The most frequent type of dementia was Alzheimer's disease (47.1%), followed by vascular pathology (28.9%), mixed forms (17.2%) and other types (6.8%). In MCI, 69.5% were of amnestic multiple domain type and 14.3% were non-amnestic multiple domain, while 41.3% were of vascular and 35.8% of neurodegenerative etiology. Mean age was 79.6±6.7 years and 64.7% were women in dementia cases whereas mean age was 76.4±6.9 years and 62.1% were women in MCI. Mean years of schooling was 4.95±4.09 years and 6.87±4.71, while mean time between onset of symptoms and clinical diagnosis was 3.2±2.6 years and 2.67±2.69 years, in dementia and MCI, respectively. CONCLUSION: The determination of the main types of dementia and MCI in Costa Rica and their main features has allowed the registration of comprehensive, hitherto unavailable information that will be useful for the management and strategic planning of public health care.

Two experiments were carried out to evaluate selenium and vitamin E (Se-VE) in Pelibuey ewes. The application of Se-VE took place two days before progesterone (P) was no longer provided. The onset of estrus, the number of corpus luteum, fertility, lambing, fecundity and prolificacy were recorded. In the first experiment, 125 females were used and randomly assigned to one of eight treatments. P (T1; n = 12), P + Se-VE (T2; n = 12), P + Equine chorionic gonadotropin (eCG; T3; n = 12), P + Directed feeding (AD; T4; n = 12), P + Se-VE + eCG (T5; n = 12), P + Se-VE + AD (T6; n = 12), P + eCG + AD (T7; n = 12) and P + Se-VE + eCG + AD (T8; n = 12). Later, a ninth treatment was added (T9, Without drugs (SF), n = 29). In the second experiment, 178 females were used and randomly assigned to one of the following treatments. P (TI; n = 62), P + Se-VE + eCG (T2; n = 62) and SF (T3; n = 54). Data were analysed with a Chi-square test for variables in percentages, and with an analysis of variance for quantitative variables. In the first experiment, the beginning of estrus was different (p < 0.05) for T3 and T5. T9 was different from the other treatments (p < 0.05) for fertility, lambing and fecundity. In the second experiment, T2 was different (p < 0.05) for the onset of estrus. T2 and T3 were different (p < 0.05) for fertility, lambing and fecundity. It is suggested that the administration of Se-VE + eCG may be used as a strategy to improve estrus synchronisation and to homogenise its appearance in less time, without decreasing the reproductive efficiency of the Pelibuey ewes.

Se realizaron dos experimentos con la finalidad de evaluar el selenio y la vitamina E (Se-VE) en ovejas Pelibuey. La aplicación de Se-VE se realizó dos días antes del retiro de la progesterona (P). Se observó el inicio de estro, número de cuerpos lúteos, fertilidad, parición, fecundidad y prolifícidad. En el primer experimento se utilizaron 125 hembras asignadas al azar a uno de ocho tratamientos. P (T1; n = 12), P + Se-VE (T2; n = 12), P + Gonadotropina coriónica equina (eCG; T3; n = 12), P + Alimentación dirigida (AD; T4; n = 12), P + Se-VE + eCG (T5; n = 12), P + Se-VE + AD (T6; n = 12), P + eCG + AD (T7; n = 12) y P + Se-VE + eCG + AD (T8; n = 12). Posteriormente se adicionó un noveno tratamiento (T9, Sin fármacos (SF), n = 29). En el segundo experimento se utilizaron 178 hembras asignadas al azar a uno de los siguientes tratamientos. P (TI; n = 62), P + Se-VE + eCG (T2; n = 62) y SF (T3; n = 54). El análisis de datos se realizó mediante pruebas de Chi-cuadrada para las variables en porcentaje, y análisis de varianza para las variables cuantitativas. En el experimento uno, el inicio al estro fue diferente (p < 0.05) para T3 y T5. El T9 fue diferente del resto de los tratamientos (p < 0.05) para fertilidad, parición y fecundidad.En el experimento dos T2 fue diferente (p < 0.05) para el inicio del estro. El T2 y T3 fueron diferentes (p < 0.05) para fertilidad, parición y fecundidad Se sugiere que la administración de Se-VE + eCG puede utilizarse como una estrategia para mejorar la sincronización de estros y homogenizar su presentación en un menor tiempo, sin disminuir la eficiencia reproductiva de las ovejas Pelibuey.

Background. Respiratory syncytial virus (RSV) is the most frequent etiologic agent causing lower respiratory tract infection in children <2 years of age. Between 0.5 and 3% of patients will require hospitalization. The aim of this study was to estimate the direct medical cost of treating children <2 years old with suspicion of RSV at the Instituto Mexicano del Seguro Social (IMSS). Methods. Direct medical costs were estimated from an institutional perspective. Medical records were reviewed from patients <2 years of age who attended emergency services in second-level hospitals including subjects who required hospitalization. Estimated costs were obtained with the microcosting technique using the institutional costs from IMSS (year 2010). Costs were reported in USD (year 2011). Results. When analyzing total medical costs, outpatient management yielded a cost of $230.0 ± $10.30 U.S. dollars (USD), whereas hospitalized patients exhibited an average cost of $8,313.20 ± $595.30 USD. The main components of outpatient management costs were emergency visits, specialist consultations and diagnostic testing (41.6%, 32.7% and 10.7% of the total cost, respectively). In the case of hospitalized patients, intensive care unit cost (89.3%) and overall hospitalization cost (6.5%) represented 95.7% of the total cost. Conclusions. RSV is a disease that represents a significant economic burden for health care institutions, although most patients are treated on an outpatient basis.

OBJECTIVE: The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. MATERIAL AND METHODS: A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009. RESULTS: ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760. CONCLUSIONS: Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.

OBJETIVO: El estudio evaluó la razón costo-efectividad incremental (RCEI) de profilaxis con palivizumab para reducción de complicaciones asociadas al virus sincicial respiratorio en prematuros en México. MATERIAL Y MÉTODOS: Se empleó un árbol de decisiones en los grupos pretérmino [<29 y 29-32 semanas de edad gestacional (SEG)], empleando datos epidemiológicos y costos locales; la eficacia se obtuvo con una revisión sistemática, evaluando a los pacientes de acuerdo con su esperanza de vida. Se empleó la perspectiva del Sistema Nacional de Salud. Las medidas de eficacia fueron AVG y AVAC. Los costos son reportados en dólares de 2009. RESULTADOS: Las RCEI por AVG resultaron de USD $25 029 y USD $29 637 para <29 y 29-32 SEG, mientras que las RCEI por AVAC fueron de USD $17 532 y USD $20 760. CONCLUSIONES: La profilaxis con palivizumab en pacientes recién nacidos pretérmino ≤32 semanas de edad resultó ser una alternativa costo-efectiva.

OBJECTIVE: The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. MATERIAL AND METHODS: A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009. RESULTS: ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760. CONCLUSIONS: Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.

OBJETIVO: El estudio evaluó la razón costo-efectividad incremental (RCEI) de profilaxis con palivizumab para reducción de complicaciones asociadas al virus sincicial respiratorio en prematuros en México. MATERIAL Y MÉTODOS: Se empleó un árbol de decisiones en los grupos pretérmino [<29 y 29-32 semanas de edad gestacional (SEG)], empleando datos epidemiológicos y costos locales; la eficacia se obtuvo con una revisión sistemática, evaluando a los pacientes de acuerdo con su esperanza de vida. Se empleó la perspectiva del Sistema Nacional de Salud. Las medidas de eficacia fueron AVG y AVAC. Los costos son reportados en dólares de 2009. RESULTADOS: Las RCEI por AVG resultaron de USD $25 029 y USD $29 637 para <29 y 29-32 SEG, mientras que las RCEI por AVAC fueron de USD $17 532 y USD $20 760. CONCLUSIONES: La profilaxis con palivizumab en pacientes recién nacidos pretérmino ≤32 semanas de edad resultó ser una alternativa costo-efectiva.

OBJECTIVE: To estimate the cost-effectiveness ratio of surfactant rescue treatment of premature infants with respiratory distress syndrome (RDS) who are covered by the Medical Insurance for a New Generation. MATERIALS AND METHODS: A cost-effectiveness evaluation was conducted from the third-payer perspective. Comparisons were made between the use of bovine surfactant (BS) therapy and without BS therapy. A decision tree model with a lifetime horizon was used where the measurements of effectiveness were life years gained (LYG) and quality-adjusted life years (QALYs). A 5% discount rate was considered for costs and health outcomes. All costs are expressed in Mexican pesos 2009. RESULTS: Incremental cost-effectiveness ratios (ICER) were MXN$136670 per LYG and MXN$125250 per QALY. CONCLUSION: Surfactant therapy was confirmed as a cost-effective strategy in accordance with World Health Organization criteria of three per capita gross domestic product (GDP) per QALY in premature infants with RDS in Mexico.

OBJETIVO: Estimar la razón de costo efectividad incremental del tratamiento de surfactante de rescate en pacientes pretérmino con Síndrome de Dificultad Respiratoria (SDR) cubiertos por el Seguro Médico para una Nueva Generación. MATERIAL Y MÉTODOS: Evaluación de costo-efectividad desde la perspectiva del tercer pagador. Los comparadores fueron la terapia de surfactante bovino y la alternativa de no emplear ésta. Se utilizó un árbol de decisión que consideró la esperanza de vida como horizonte temporal y las medidas de efectividad fueron los años de vida ganados (AVG) y los años de vida ajustados por calidad de vida ( AVAC).Resultados en pesos mexicanos del 2009. RESULTADOS: Las RCEI por AVG y AVAC fueron de MXN$136670 y MXN$125250. CONCLUSIÓN: La razón de costo por AVG y AVAC para la terapia de surfactantes en pacientes prematuros con SDR en México fue menor a tres veces el PIB per cápita, por lo que es una estrategia costo-efectiva según los criterios de la OMS.

OBJECTIVE: To estimate the cost-effectiveness ratio of surfactant rescue treatment of premature infants with respiratory distress syndrome (RDS) who are covered by the Medical Insurance for a New Generation. MATERIALS AND METHODS: A cost-effectiveness evaluation was conducted from the third-payer perspective. Comparisons were made between the use of bovine surfactant (BS) therapy and without BS therapy. A decision tree model with a lifetime horizon was used where the measurements of effectiveness were life years gained (LYG) and quality-adjusted life years (QALYs). A 5% discount rate was considered for costs and health outcomes. All costs are expressed in Mexican pesos 2009. RESULTS: Incremental cost-effectiveness ratios (ICER) were MXN$136670 per LYG and MXN$125250 per QALY. CONCLUSION: Surfactant therapy was confirmed as a cost-effective strategy in accordance with World Health Organization criteria of three per capita gross domestic product (GDP) per QALY in premature infants with RDS in Mexico.

OBJETIVO: Estimar la razón de costo efectividad incremental del tratamiento de surfactante de rescate en pacientes pretérmino con Síndrome de Dificultad Respiratoria (SDR) cubiertos por el Seguro Médico para una Nueva Generación. MATERIAL Y MÉTODOS: Evaluación de costo-efectividad desde la perspectiva del tercer pagador. Los comparadores fueron la terapia de surfactante bovino y la alternativa de no emplear ésta. Se utilizó un árbol de decisión que consideró la esperanza de vida como horizonte temporal y las medidas de efectividad fueron los años de vida ganados (AVG) y los años de vida ajustados por calidad de vida ( AVAC).Resultados en pesos mexicanos del 2009. RESULTADOS: Las RCEI por AVG y AVAC fueron de MXN$136670 y MXN$125250. CONCLUSIÓN: La razón de costo por AVG y AVAC para la terapia de surfactantes en pacientes prematuros con SDR en México fue menor a tres veces el PIB per cápita, por lo que es una estrategia costo-efectiva según los criterios de la OMS.

Background. In order to evaluate the effectiveness of the bovine surfactant (BS) for the treatment of newborns with respiratory distress syndrome (RDS), we performed a systematic review and meta-analysis. Methods. Randomized-controlled trials (RCT) assessing the BS in comparison with placebo for the treatment of prematures with RDS were included. Outcome measures evaluated were: mortality, morbidity, days on mechanical ventilation (MV) and length of hospitalization. RCT published until 2010 were obtained from Medline, EMBASE and Cochrane Collaboration. Selection of included studies was based on a peer-review process. For the meta-analyses, relative risk (RR) and weighted mean differences (WMD) were calculated, with 95% confidence intervals (95%CI). Results. From 865 titles and abstracts obtained, 89 papers were reviewed and 12 RCT were selected. Among the outcome measures assessed, BS was shown to be effective in only in four: mortality (RR 0.73, 95% CI 0.60-0.88, p =0.001), pneumothorax (RR 0.41; 95% CI 0.33-0.51, p <0.0001), pulmonary interstitial emphysema (RR 0.45; 95% CI 0.36-0.56, p <0.0001) and on days of MV (WMD -9.57; 95% CI -16.58 to -2.56, p =0.007). However, we did not find any positive effect on bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage or abnormal neurological development. Conclusions. In newborns with RDS, bovine surfactant is effective regarding mortality, pneumothorax, and pulmonary interstitial emphysema, as well as on decrease in the length of MV and possibly on length of hospitalization.

Introducción. Con el propósito de determinar la efectividad del surfactante bovino (SB) para el tratamiento del síndrome de dificultad respiratoria (SDR) en recién nacidos prematuros (RNP), se realizó una revisión sistemática y meta-análisis. Métodos. Se incluyeron ensayos clínicos aleatorizados (ECA) donde se comparó SB con placebo. Las variables de desenlace fueron: mortalidad, morbilidad, días de ventilación mecánica (VM) y de estancia hospitalaria. Los ECA publicados hasta el 2010 se identificaron en Medline, EMBASE y la Colaboración Cochrane. La selección de los ECA fue por pares. En el meta-análisis se calculó riesgo relativo (RR) y diferencia de medias ponderada (DMP), con intervalos de confianza al 95% (IC95%). Resultados. De 865 títulos y resúmenes, se revisaron 89 artículos en extenso y se seleccionaron 12 ECA. El SB se mostró efectivo en cuatro variables: mortalidad (RR 0.73, IC95% 0.60-0.88, P =0.001), neumotórax (RR 0.41; IC95% 0.33-0.51, P <0.0001), enfisema intersticial pulmonar (RR 0.45; IC95% 0.36-0.56, P <0.0001) y días de VM (DMP -9.57; IC95% -16.58, -2.56, P =0.007). Para otras, como displasia broncopulmonar, enterocolitis necrosante, hemorragia intraventricular o alteración del desarrollo neurológico, no se determinó ventaja con SB. Conclusiones. En RNP, el uso de SB es efectivo al disminuir la mortalidad, la frecuencia de neumotórax y enfisema intersticial pulmonar, así como el tiempo de VM y, posiblemente, el de estancia hospitalaria.

Objective. To estimate the economic and health burden of childhood obesity in Mexican population over the long term. This study estimates healthcare costs due to child obesity in Mexican children from 2006-2050. A hypothetic 5-11-year-old obese cohort based on prevalence, incidence, and clinical development data was modelled. Cost allocation considerations include type 2 diabetes mellitus and high blood pressure. The first cases of diabetes mellitus and with a risk of high blood pressure appears in the year 2015. When the first group of children is 40 years old, there is a considerable increase in obesity-related complications. A total of 67.3% of the cohort would have obesity in the year 2050. The cost of obesity care would be $57 678 million Mexican pesos. The magnitude of obesity reported is at worrisome levels in all age groups, showing costs that would consume a high percentage of the health system’s resources.

Objetivo. Estimar la carga económica y en salud de la obesidad en niños mexicanos en un horizonte de largo plazo. Estimación de costos médicos atribuibles a la obesidad en niños mexicanos durante 2006-2050. Una cohorte hipotética de 5-11 años de edad obesa se modeló con base en prevalencia, incidencia y evolución clínica. Los costos considerados fueron por diabetes mellitus tipo 2 e hipertensión arterial. En 2015 se presentarían los primeros casos de diabetes mellitus y de hipertensión arterial. Cuando el primer grupo de niños cumpla 40 años aumentarán considerablemente las complicaciones de la obesidad. Para 2050, 67.3% de la cohorte tendría obesidad. El costo de atención a la obesidad será de $57 678 millones de pesos. La magnitud de la obesidad se reporta en niveles preocupantes en todas las edades, con costos que consumirán buena parte de los recursos del sistema de salud.